Elena M. Teodorescu

Aalborg, Denmark

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

Mitigating Teclistamab Toxicity: Prophylactic Tocilizumab and Timing of Immunoglobulin Replacement Therapy in a Nationwide Cohort.

Mitigating Teclistamab Toxicity: Prophylactic Tocilizumab and Timing of Immunoglobulin Replacement Therapy in a Nationwide Cohort.

Journal: American journal of hematology
Published: March 09, 2026

Bone progression in multiple myeloma: Benefit of zoledronic acid for patients achieving at least Very Good Partial Response and prognostic value of bone turnover markers.

Bone progression in multiple myeloma: Benefit of zoledronic acid for patients achieving at least Very Good Partial Response and prognostic value of bone turnover markers.

Journal: British journal of haematology
Published: February 20, 2026

Nationwide implementation of lenalidomide maintenance in multiple myeloma: A retrospective, real-world study.

Nationwide implementation of lenalidomide maintenance in multiple myeloma: A retrospective, real-world study.

Journal: EJHaem
Published: November 27, 2023

The real-world use and efficacy of pomalidomide for relapsed and refractory multiple myeloma in the era of CD38 antibodies.

The real-world use and efficacy of pomalidomide for relapsed and refractory multiple myeloma in the era of CD38 antibodies.

Journal: EJHaem
Published: July 13, 2023

Potential value of pre-planned imaging of bone disease in multiple myeloma.

Potential value of pre-planned imaging of bone disease in multiple myeloma.

Journal: Blood cancer journal
Published: December 06, 2022

The clinical course and life expectancy of patients with multiple myeloma who discontinue their first daratumumab-containing line of therapy.

The clinical course and life expectancy of patients with multiple myeloma who discontinue their first daratumumab-containing line of therapy.

Journal: American journal of hematology
Published: September 10, 2021

Outcome of treatment with carfilzomib before and after treatment with daratumumab in relapsed or refractory multiple myeloma patients.

Outcome of treatment with carfilzomib before and after treatment with daratumumab in relapsed or refractory multiple myeloma patients.

Journal: Hematological oncology
Published: June 11, 2021

The real-world outcomes of multiple myeloma patients treated with daratumumab.

The real-world outcomes of multiple myeloma patients treated with daratumumab.

Journal: PloS one
Published: March 19, 2021

Prothrombotic abnormalities in patients with multiple myeloma and monoclonal gammopathy of undetermined significance.

Prothrombotic abnormalities in patients with multiple myeloma and monoclonal gammopathy of undetermined significance.

Journal: Thrombosis research
Published: November 17, 2020

Clinically-suspected cast nephropathy: A retrospective, national, real-world study.

Clinically-suspected cast nephropathy: A retrospective, national, real-world study.

Journal: American journal of hematology
Published: May 13, 2020

Extracellular vesicle-associated procoagulant phospholipid and tissue factor activity in multiple myeloma.

Extracellular vesicle-associated procoagulant phospholipid and tissue factor activity in multiple myeloma.

Journal: PloS one
Published: October 09, 2018

Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish population.

Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish population.

Journal: PloS one
Published: May 31, 2017
Showing 1-12 of 13

Last Updated: 09/26/2026